Lyra Therapeutics, Inc. (LYRA) NASDAQ
0.44
-0.05989999(-11.98%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.44
-0.05989999(-11.98%)
Currency In USD
| Previous Close | 0.5 |
| Open | 0.46 |
| Day High | 0.48 |
| Day Low | 0.44 |
| 52-Week High | 37.5 |
| 52-Week Low | 0.44 |
| Volume | 77,920 |
| Average Volume | 106,352 |
| Market Cap | 781,126 |
| PE | -0.02 |
| EPS | -18.62 |
| Moving Average 50 Days | 1.82 |
| Moving Average 200 Days | 5.95 |
| Change | -0.06 |
Data not available
Lyra Therapeutics Provides Corporate Update
GlobeNewswire Inc.
Jan 12, 2026 12:00 PM GMT
WATERTOWN, Mass., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”) today announced that its Board of Directors has decided to suspend further development of LYR-210, the Company’s lead product candi
Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeting WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (
Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Jun 27, 2025 12:00 PM GMT
Upfront Gross Proceeds of $5.0 Million, with Up to Approximately $9.8 Million of Additional Gross Proceeds Assuming the Cash Exercise in Full of Private Placement WarrantsWATERTOWN, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (